About us

Rosetta is a specialised UK-based venture capital firm focused on the life sciences and medical device sectors. Our investment approach is global, building leading healthcare companies and groundbreaking technologies with the potential to enhance human lives. Our primary focus is direct secondary transactions, offering adaptable liquidity solutions to investors and corporations.

With a history spanning over 20 years, Rosetta has engaged in 50+ venture investments through direct secondary transactions, demonstrating extensive proficiency in executing complex transactions effectively

As secondary investors, we address the needs of investors or corporations aiming to divest part or all of their investment assets, as well as those seeking additional capital and resources to enhance their investment strategies

We inject fresh capital into companies during follow-on financings, providing crucial support during pivotal growth stages

Our seasoned team collaborates strategically with portfolio company boards, management teams, and co-investors, facilitating successful corporate partnerships, IPOs, and trade sales. Our goal is to enhance the value of our investments and contribute to the advancement of healthcare and technology

We have an exceptional track record over 20+ years:

0
founded in

Global investment horizon

with a track record of executing transactions across North America and Europe

funds

raised and deployed across the life sciences and medical device sectors
$

million+

in historical commitments
0 +
IPO and M&A exits, mostly on NASDAQ and European exchanges

Find out more

Our focus

We are a venture capital firm focused on the life sciences and medical device sectors. We invest through direct secondary transactions to provide flexible liquidity solutions to investors or corporations.

Case studies

We have an experienced investment team that has a long history of completing secondary transactions with European and North American healthcare investors to acquire equity positions in portfolio companies.